ClinicalTrials.gg
CompletedNCT01663402Updated Mar 18, 2019Results posted

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

A Phase 3 interventional study of Alirocumab and Placebo in Atherosclerotic Cardiovascular Disease, sponsored by Sanofi. Completed at 1,388 sites in 57 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-03-18.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18,924
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Enrollment
3rd of 328
18,924 · median 119
Started
2012
with 18 others
Phase 3
61 of 468
6 open now
Registered
243rd of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 3rd largest by enrollment of the 328 interventional ones that give a count, is one of 19 that started in 2012, is one of 61 in phase 3, and was the 243rd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia.

Secondary Objectives:

  • To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, CHD deaths, CV deaths, all cause mortality).
  • To evaluate the safety and tolerability of alirocumab.
  • To evaluate the effect of alirocumab on lipid parameters.
Read the detailed description

18924 number of participants aged >= 40 years old were randomized in the study.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Recently (\< 52 weeks) hospitalized for ACS.

Exclusion criteria

Exclusion criteria:

  • Age \< 40 years.
  • ACS event occurring more than 52 weeks prior to randomization visit.
  • LDL-C likely to be \<70 mg/dL (\<1.81 mmo/L), and apolipoprotein B (ApoB) \<80 mg/dL (\<0.8 g/L), and non - high-density lipoprotein cholesterol (HDL-C) \<100 mg/dL (\<2.59 mmol/L) with evidence-based medical and dietary management of dyslipidemia.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18,924 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.

    Drug: Placebo · Drug: LMT

  • Experimental
    Alirocumab 75 mg Q2W/Up to 150 mg Q2W

    Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels \>=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were \<25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were \<15 mg/dL (0.39 mmol/L).

    Drug: Alirocumab · Drug: LMT

Interventions

  • Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

    Also known as: SAR236553, REGN727, Praluent®

  • DrugPlacebo

    Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

  • DrugLMT

    Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study

    All MACE positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the analysis of the composite cardiovascular (CV) outcome measure comprised of Coronary Heart Disease (CHD) death, non-fatal Myocardial Infarction (MI), fatal and non-fatal ischemic stroke (IS), or unstable angina (UA) requiring hospitalization. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of MACE over time. Percentage of observed participants with outcome measure events during the study were reported.

    Time frame: From randomization up to 64 months

Secondary outcomes

  1. Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study

    All CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death, non-fatal non-fatal MI, UA requiring hospitalization, or ischemia-driven coronary revascularization procedure. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.

    Time frame: From randomization up to 64 months

  2. Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study

    All Major CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death and non-fatal MI. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any major CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.

    Time frame: From randomization up to 64 months

  3. Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study

    All CV events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CV endpoint comprised of any non-fatal CHD event, any CV death and non-fatal IS. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CV event over time. Percentage of observed participants with outcome measure events during the study were reported.

    Time frame: From randomization up to 64 months

  4. Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study

    All-cause mortality, non-fatal MI and non-fatal IS positively adjudicated by CEC in a blinded fashion, were used in the analysis of this endpoint. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of all-cause mortality, non-fatal MI and non-fatal IS over time. Percentage of observed participants with outcome measure events during the study were reported.

    Time frame: From randomization up to 64 months

  5. Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CHD death over time. Percentage of observed participants with CHD death (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  6. Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CV death over time. Percentage of observed participants with CV death (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  7. Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the all-cause death over time. Percentage of observed participants with all-cause death (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  8. Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any non-fatal MI over time. Percentage of observed participants with any non-fatal MI (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  9. Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of fatal or any non-fatal IS over time. Percentage of observed participants with fatal or any non-fatal IS (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  10. Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any UA requiring hospitalization over time. Percentage of observed participants with any UA requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  11. Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any ischemia-driven coronary revascularization procedure over time. Percentage of observed participants with any ischemia-driven coronary revascularization procedure (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

  12. Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study

    Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHF requiring hospitalization over time. Percentage of observed participants with any CHF requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.

    Time frame: From randomization up to 64 months

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: ITT Analysis

    Adjusted means and standard errors at Month 4, 12 and 48 from multiple imputation approach (to account for missing data) followed by analyses of covariance (ANCOVA) model with the fixed categorical effect of treatment group and the continuous fixed covariate of baseline LDL-C value, including all available post-baseline data from Month 1 up to Month 48 regardless of status on- or off-treatment.

    Time frame: Baseline, Months 4, 12 and 48

  2. Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: On-Treatment Analysis

    Adjusted Least-squares (LS) means and standard errors at Month 4, 12 and 48 were obtained from a mixed-effect model with repeated measures (MMRM) including available post-baseline on-treatment data from Month 1 up to Month 48 (i.e. up to 21 days after last injection).

    Time frame: Baseline, Months 4, 12 and 48

07

Results

Posted Mar 18, 2019

Participant flow

The study was conducted at 1387 sites in 57 countries. Of these, 1328 active sites randomized at least 1 participant. Overall, 35,437 participants were screened between 11 October 2012 and 17 Jan 2017; of whom 16,513 were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Started94629462
Treated94439451
Completed79477378
Not completed15152084
Withdrew: Randomized but not treated1911
Withdrew: Adverse event347362
Withdrew: Two consecutive ldl-c <15 mg/dl0730
Withdrew: Poor compliance to protocol529454
Withdrew: Physician decision7762
Withdrew: Site terminated by sponsor13
Withdrew: Participant moved139104
Withdrew: Withdrawal by subject11891
Withdrew: Related to study drug administration96105
Withdrew: Lost to follow-up1715
Withdrew: Other than specified above172147

Outcome measures

PrimaryTime to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study

All MACE positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the analysis of the composite cardiovascular (CV) outcome measure comprised of Coronary Heart Disease (CHD) death, non-fatal Myocardial Infarction (MI), fatal and non-fatal ischemic stroke (IS), or unstable angina (UA) requiring hospitalization. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of MACE over time. Percentage of observed participants with outcome measure events during the study were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study11.19.5
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.0003 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.85 · 95% CI 0.78 to 0.93
SecondaryTime to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study

All CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death, non-fatal non-fatal MI, UA requiring hospitalization, or ischemia-driven coronary revascularization procedure. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study14.312.7
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.0013 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.88 · 95% CI 0.81 to 0.95
SecondaryTime to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study

All Major CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death and non-fatal MI. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any major CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study9.58.4
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.0060 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.88 · 95% CI 0.80 to 0.96
SecondaryTime to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study

All CV events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CV endpoint comprised of any non-fatal CHD event, any CV death and non-fatal IS. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CV event over time. Percentage of observed participants with outcome measure events during the study were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study15.613.7
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.0003 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.87 · 95% CI 0.81 to 0.94
SecondaryTime to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study

All-cause mortality, non-fatal MI and non-fatal IS positively adjudicated by CEC in a blinded fashion, were used in the analysis of this endpoint. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of all-cause mortality, non-fatal MI and non-fatal IS over time. Percentage of observed participants with outcome measure events during the study were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study11.910.3
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.0003 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.86 · 95% CI 0.79 to 0.93
SecondaryTime to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CHD death over time. Percentage of observed participants with CHD death (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study2.32.2
Statistical analysis
  • Placebo vs Alirocumab 75 mg Q2W/Up to 150 mg Q2W · Log Rank · p = 0.3824 (Threshold for statistical significance at 0.0498 level.) · Hazard ratio (hr): 0.92 · 95% CI 0.76 to 1.11
SecondaryTime to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CV death over time. Percentage of observed participants with CV death (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study2.92.5
SecondaryTime to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the all-cause death over time. Percentage of observed participants with all-cause death (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study4.13.5
SecondaryTime to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any non-fatal MI over time. Percentage of observed participants with any non-fatal MI (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study7.66.6
SecondaryTime to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of fatal or any non-fatal IS over time. Percentage of observed participants with fatal or any non-fatal IS (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study1.61.2
SecondaryTime to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any UA requiring hospitalization over time. Percentage of observed participants with any UA requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study0.60.4
SecondaryTime to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any ischemia-driven coronary revascularization procedure over time. Percentage of observed participants with any ischemia-driven coronary revascularization procedure (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study8.87.7
SecondaryTime to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study

Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHF requiring hospitalization over time. Percentage of observed participants with any CHF requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.

Time frame:
From randomization up to 64 months
Reported as:
Number · percentage of participants
Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study
percentage of participantsPlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study1.91.9
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: ITT Analysis

Adjusted means and standard errors at Month 4, 12 and 48 from multiple imputation approach (to account for missing data) followed by analyses of covariance (ANCOVA) model with the fixed categorical effect of treatment group and the continuous fixed covariate of baseline LDL-C value, including all available post-baseline data from Month 1 up to Month 48 regardless of status on- or off-treatment.

Time frame:
Baseline, Months 4, 12 and 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: ITT Analysis
Percent changePlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Month 44.4 ± 0.3-55.8 ± 0.3
Month 128.0 ± 0.4-45.7 ± 0.4
Month 4816.4 ± 1.8-23.5 ± 1.6
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: On-Treatment Analysis

Adjusted Least-squares (LS) means and standard errors at Month 4, 12 and 48 were obtained from a mixed-effect model with repeated measures (MMRM) including available post-baseline on-treatment data from Month 1 up to Month 48 (i.e. up to 21 days after last injection).

Time frame:
Baseline, Months 4, 12 and 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: On-Treatment Analysis
Percent changePlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2W
Month 44.4 ± 0.3-58.3 ± 0.3
Month 128.2 ± 0.4-52.8 ± 0.4
Month 4814.6 ± 1.0-40.1 ± 1.0

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form until the end of study (Month 64) regardless of seriousness or relationship to Investigational Medicinal Product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo278/9,443 (2.9%)2,350/9,443 (24.9%)2,181/9,443 (23.1%)
Alirocumab238/9,451 (2.5%)2,202/9,451 (23.3%)2,203/9,451 (23.3%)
Most frequent serious events
Showing 10 of 1,527
Most frequent serious events
EventPlaceboAlirocumab
Non-Cardiac Chest PainGeneral disorders222/9443219/9451
Angina PectorisCardiac disorders133/9443113/9451
PneumoniaInfections and infestations108/944396/9451
Atrial FibrillationCardiac disorders98/944382/9451
SyncopeNervous system disorders73/944367/9451
Acute Kidney InjuryRenal and urinary disorders62/944357/9451
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders51/944338/9451
OsteoarthritisMusculoskeletal and connective tissue disorders46/944350/9451
Peripheral Arterial Occlusive DiseaseVascular disorders47/944327/9451
Sudden Cardiac DeathGeneral disorders42/944336/9451
Most frequent other events
Most frequent other events
EventPlaceboAlirocumab
HypertensionVascular disorders574/9443542/9451
NasopharyngitisInfections and infestations532/9443567/9451
MyalgiaMusculoskeletal and connective tissue disorders496/9443522/9451
Blood Creatine Phosphokinase IncreasedInvestigations488/9443457/9451
Non-Cardiac Chest PainGeneral disorders462/9443481/9451

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2WTotal
Mean58.6 ± 9.458.5 ± 9.358.6 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2WTotal
Female237223904762
Male7090707214162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2WTotal
Hispanic or Latino155515813136
Not Hispanic or Latino7721770015421
Unknown or Not Reported186181367
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAlirocumab 75 mg Q2W/Up to 150 mg Q2WTotal
White7524750015024
Black or African American238235473
Asian124712512498
Other449469918
Unknown268
08

Study locations

1,388 sites
  • Investigational Site Number 840163
    Birmingham, Alabama 35235, United States
  • Investigational Site Number 840060
    Birmingham, Alabama 35294, United States
  • Investigational Site Number 840117
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840192
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840121
    Mobile, Alabama 36604, United States
  • Investigational Site Number 840319
    Mobile, Alabama 36695, United States
  • Investigational Site Number 840332
    Atlantis, Arizona 33462, United States
  • Investigational Site Number 840320
    Newport Beach, Arizona 92663, United States
  • Investigational Site Number 840103
    Tucson, Arizona 85724, United States
  • Investigational Site Number 840084
    Tucson, Arizona, United States
  • Investigational Site Number 840139
    Banning, California, United States
  • Investigational Site Number 840286
    Beverly Hills, California 90210, United States
  • Investigational Site Number 840246
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840353
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840341
    Carmichael, California 95608, United States
  • Investigational Site Number 840299
    Chula Vista, California 91910, United States
  • Investigational Site Number 840164
    Fresno, California 93721, United States
  • Investigational Site Number 840076
    Fullerton, California 92835, United States
  • Investigational Site Number 840073
    Huntington Beach, California 92648, United States
  • Investigational Site Number 840092
    La Jolla, California 92093, United States
  • Investigational Site Number 840208
    Long Beach, California 90801, United States
  • Investigational Site Number 840068
    Long Beach, California 90822, United States
  • Investigational Site Number 840269
    Los Alamitos, California 90720, United States
  • Investigational Site Number 840009
    Los Angeles, California 90073, United States
  • Investigational Site Number 840282
    Los Angeles, California 90095, United States
  • Investigational Site Number 840019
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840336
    Moreno Valley, California 92553, United States
  • Investigational Site Number 840124
    Northridge, California 91325, United States
  • Investigational Site Number 840251
    Pasadena, California 91105, United States
  • Investigational Site Number 840289
    Pasadena, California 91105, United States
  • Investigational Site Number 840312
    Port Hueneme, California 93041, United States
  • Investigational Site Number 840261
    San Diego, California 92120, United States
  • Investigational Site Number 840310
    San Diego, California 92120, United States
  • Investigational Site Number 840024
    San Diego, California, United States
  • Investigational Site Number 840071
    Santa Ana, California 92704, United States
  • Investigational Site Number 840236
    Santa Rosa, California 95405, United States
  • Investigational Site Number 840012
    Torrance, California, United States
  • Investigational Site Number 840096
    Aurora, Colorado 80012, United States
  • Investigational Site Number 840037
    Colorado Springs, Colorado 80909, United States
  • Investigational Site Number 840189
    Denver, Colorado 80220, United States
  • Investigational Site Number 840122
    Bridgeport, Connecticut 06606, United States
  • Investigational Site Number 840219
    Guilford, Connecticut 06437, United States
  • Investigational Site Number 840347
    Altamonte Springs, Florida 32714, United States
  • Investigational Site Number 840066
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840079
    Daytona Beach, Florida 32114, United States
  • Investigational Site Number 840051
    Daytona Beach, Florida 32117, United States
  • Investigational Site Number 840368
    Delray Beach, Florida 33484, United States
  • Investigational Site Number 840242
    Fort Lauderdale, Florida 33308, United States
  • Investigational Site Number 840134
    Gainesville, Florida 32608, United States
  • Investigational Site Number 840327
    Hollywood, Florida 33021, United States
  • Investigational Site Number 840153
    Hudson, Florida 34667, United States
  • Investigational Site Number 840105
    Hudson, Florida, United States
  • Investigational Site Number 840253
    Jacksonville, Florida 32204, United States
  • Investigational Site Number 840141
    Jacksonville, Florida 32209, United States
  • Investigational Site Number 840042
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840206
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840063
    Jacksonville, Florida 32258, United States
  • Investigational Site Number 840002
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840119
    Largo, Florida, United States
  • Investigational Site Number 840241
    Miami Beach, Florida 33140, United States
  • Investigational Site Number 840210
    Mount Clemens, Florida, United States
  • Investigational Site Number 840366
    New Port Richey, Florida 34653, United States
  • Investigational Site Number 840311
    Palm Beach Gardens, Florida 33410, United States
  • Investigational Site Number 840280
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840054
    Panama City, Florida 32401, United States
  • Investigational Site Number 840239
    Pembroke Pines, Florida 33024, United States
  • Investigational Site Number 840044
    Pensacola, Florida 32501, United States
  • Investigational Site Number 840367
    Plantation, Florida 33317, United States
  • Investigational Site Number 840132
    Safety Harbor, Florida 34695, United States
  • Investigational Site Number 840061
    Safety Harbor, Florida, United States
  • Investigational Site Number 840247
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840264
    Tampa, Florida 33606, United States
  • Investigational Site Number 840082
    Tampa, Florida 33613, United States
  • Investigational Site Number 840213
    Trinity, Florida 34655, United States
  • Investigational Site Number 840165
    Wellington, Florida 33449, United States
  • Investigational Site Number 840323
    West Palm Beach, Florida 33401, United States
  • Investigational Site Number 840075
    Atlanta, Georgia, United States
  • Investigational Site Number 840176
    Augusta, Georgia 30901, United States
  • Investigational Site Number 840048
    Covington, Georgia 30014, United States
  • Investigational Site Number 840065
    Cumming, Georgia 30041, United States
  • Investigational Site Number 840356
    Thomasville, Georgia 31792, United States
  • Investigational Site Number 840114
    Tucker, Georgia 30084, United States
  • Investigational Site Number 840211
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840237
    Arlington Heights, Illinois 60005, United States
  • Investigational Site Number 840292
    Chicago, Illinois 60612, United States
  • Investigational Site Number 840146
    Harvey, Illinois 60426, United States
  • Investigational Site Number 840340
    Joliet, Illinois 60435, United States
  • Investigational Site Number 840196
    Peoria, Illinois 61614, United States
  • Investigational Site Number 840081
    Rock Island, Illinois 61201, United States
  • Investigational Site Number 840090
    Rock Island, Illinois 61201, United States
  • Investigational Site Number 840358
    Elkhart, Indiana 46514, United States
  • Investigational Site Number 840036
    Hammond, Indiana 46320, United States
  • Investigational Site Number 840026
    Indianapolis, Indiana, United States
  • Investigational Site Number 840102
    Muncie, Indiana 47303-3400, United States
  • Investigational Site Number 840145
    South Bend, Indiana 46601-1075, United States
  • Investigational Site Number 840154
    Ames, Iowa 50010, United States
  • Investigational Site Number 840345
    Iowa City, Iowa, United States
  • Investigational Site Number 840283
    West Des Moines, Iowa 50266, United States
  • Investigational Site Number 840335
    Kansas City, Kansas 64116, United States
  • Investigational Site Number 840089
    Kansas City, Kansas 66160-7321, United States

Showing the first 100 of 1,388 sites across 57 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hagstrom E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. PubMed 35770629 ↗
  • Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pecin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022 Oct 20;29(14):1842-1851. doi: 10.1093/eurjpc/zwac107. PubMed 35708715 ↗
  • Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagstrom E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, Simon T, Steg PG; ODYSSEY OUTCOMES Investigators. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Can J Cardiol. 2022 Oct;38(10):1542-1549. doi: 10.1016/j.cjca.2022.05.021. Epub 2022 May 27. PubMed 35644332 ↗
  • Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022 May;10(5):330-340. doi: 10.1016/S2213-8587(22)00043-2. Epub 2022 Apr 1. PubMed 35378068 ↗
  • Lopes RD, Guimaraes PO, Schwartz GG, Bhatt DL, Bittner VA, Budaj A, Dalby AJ, Diaz R, Goodman SG, Harrington RA, Jukema JW, Kiss RG, Loy M, Pordy R, Poulouin Y, Szarek M, White HD, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. Am J Med. 2022 Jul;135(7):915-918. doi: 10.1016/j.amjmed.2022.02.016. Epub 2022 Mar 14. PubMed 35296402 ↗
  • Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, Lopez-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. PubMed 34325831 ↗
  • Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Z, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. doi: 10.1177/2047487320941987. Epub 2020 Jul 27. PubMed 33755145 ↗
  • Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care. 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842. Epub 2021 Mar 15. PubMed 33722880 ↗
  • Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M; ODYSSEY OUTCOMES Committees and Investigators. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021 Mar 16;143(11):1109-1122. doi: 10.1161/CIRCULATIONAHA.120.049447. Epub 2021 Jan 13. PubMed 33438437 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
  • Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 Nov 21;41(44):4245-4255. doi: 10.1093/eurheartj/ehaa649. PubMed 33051646 ↗
  • Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, Roe MT, Lopes RD, White HD, Zeiher AM, Schwartz GG, Gabriel Steg P; ODYSSEY OUTCOMES Investigators. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 May 12;75(18):2297-2308. doi: 10.1016/j.jacc.2020.03.029. PubMed 32381160 ↗
  • Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL; ODYSSEY OUTCOMES Committees and Investigators*. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. 2020 May 19;141(20):1608-1617. doi: 10.1161/CIRCULATIONAHA.120.046524. Epub 2020 Mar 29. PubMed 32223446 ↗
  • Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057. PubMed 31948641 ↗
  • Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005858. doi: 10.1161/CIRCOUTCOMES.119.005858. Epub 2019 Nov 11. PubMed 31707826 ↗
  • Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Z, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation. 2019 Dec 17;140(25):2054-2062. doi: 10.1161/CIRCULATIONAHA.119.043826. Epub 2019 Nov 11. PubMed 31707788 ↗
  • Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2. PubMed 31475572 ↗
  • Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, Ramos Lopez GA, Roe MT, Viigimaa M, White HD, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 Sep 3;74(9):1177-1186. doi: 10.1016/j.jacc.2019.07.015. PubMed 31466614 ↗
  • Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tunon J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum In: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. doi: 10.1016/S2213-8587(19)30242-6. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21. doi: 10.1016/S2213-8587(19)30259-1. PubMed 31272931 ↗
  • Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23. Erratum In: Circulation. 2019 Jul 23;140(4):e171. doi: 10.1161/CIR.0000000000000712. PubMed 31117810 ↗
  • Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176. doi: 10.1016/j.jacc.2019.03.013. Epub 2019 Mar 18. PubMed 30898609 ↗
  • Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. PubMed 30403574 ↗
  • Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7. PubMed 25440796 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Jan 2018, 63 months.

Results were first posted in Mar 2019, 1 year 1 month after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 63 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2012
First posted
Aug 13, 2012
StartActual
Oct 2012
Primary completionActual
Jan 23, 2018
CompletionActual
Jan 23, 2018
Results first posted
Mar 18, 2019
Last update
Mar 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01663402
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 13, 2012
Start date
Oct 2012
Primary completion
Jan 23, 2018
Completion
Jan 23, 2018
Results posted
Mar 18, 2019
Last update
Mar 18, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion